Randomized comparison of a sirolimus-eluting stent with a biolimus-eluting stent in patients treated with PCI: the SORT OUT VII trial
|
|
- Lily Cooper
- 6 years ago
- Views:
Transcription
1 euro P C R Randomized comparison of a sirolimuseluting stent with a biolimuseluting stent in patients treated with PCI: the SORT OUT VII trial Lisette Okkels Jensen, Per Thayssen, Michael Maeng, Jan Ravkilde, Lars Krusell, HansHenrik Tilsted, Anders Junker, Christian Juhl Terkelsen, Karsten Tange Veien, Anne Kaltoft, Anton Boel Villadsen, Jens Aaroe, Klára Berencsi, Svend Eggert Jensen, Knud Nørregaard Hansen, Steen Dalby Kristensen, Morten Madsen, Hans Erik Bøtker Henrik Steen Hansen, Bent Raungaard, Jens Flensted Lassen, Evald Høj Christiansen Odense University Hospital, Aarhus University Hospital, Aalborg University Hospital DENMARK
2 P C R euro 2015 Potential conflicts of interest Speaker's name: Lisette Okkels Jensen I have the following potential conflicts of interest to report: Honorarium: ABBOTT VASCULAR, ASTRAZENECA, BIOTRONIK, ST. JUDE MEDICAL Institutional grant/research support: BIOSENSORS INTERNATIONAL, BIOTRONIK, ST. JUDE MEDICAL, TERUMO SORT OUT VII 1Y
3 Background Drugeluting stents have reduced the risk of instent restenosis. Compared to first generation drugeluting stents the second generation with thinner stent struts have improved safety and efficacy Persistence of polymer material on first and second generation drugeluting stent after completion of drug release has been suggested to be a trigger of a chronic inflammatory response Third generation coronary drugeluting stents with biodegradable polymers have been designed to improve safety and efficacy New ultrathin strut third generation stents have been developed and may further improve safety and efficacy SORT OUT VII 1Y
4 Primary Endpoint Objective: To compare the efficacy and safety of the thin strut, cobaltchromium biodegradable polymer sirolimuseluting Orsiro stent and the stainless steel biodegradable polymer biolimuseluting Nobori stent in an allcomer population Primary Endpoint: Target lesion failure: a composite of cardiac death, myocardial infarction (not related to other than index lesion) or target lesion revascularization within 1 year An event rate of 6.5% was assumed in each group. Sample size of patients in each treatment arm, a onesided significance level and a 90% power to detect noninferiority. Noninferiority margin of 3.0% Clinically driven event detection based on Danish registries SORT OUT VII 1Y
5 Criteria of inclusion Patient Population Inclusion period: November 2012 to February years of age or older Chronic stable coronary artery disease or acute coronary syndromes Criteria of exclusion Life expectancy less than one year Allergy to aspirin, clopidogrel, ticagrelor, sirolimus, or biolimus Participation in another randomized trial Unacceptable risk by 12month dual antiplatelet treatment Unable to provide written informed consent No restrictions were placed on number of treated lesions, treated vessels or lesion length SORT OUT VII 1Y
6 Patient Characteristics SIROLIMUSELUTING ORSIRO STENT BIOLIMUSELUTING NOBORI STENT No. of patients Age (years) 66.1 ± ± 10.8 <0.01 Male gender 74.9 % 75.2 % 0.84 Diabetes 18.7 % 18.6 % 0.94 Hypertension 58.1 % 56.4 % 0.39 Current smoker 29.1 % 32.5 % 0.07 Prior CABG 8.0 % 7.6 % 0.72 Prior PCI 19.0 % 20.4 % 0.39 Prior myocardial infarction 17.4 % 17.8 % 0.83 Body mass Index (kg/m 2 ) 27.5 ± ± Indication for PCI 0.47 Stable angina pectoris 44.3 % 43.9 % NSTEMI / Unstable angina pectoris 30.7 % 32.6 % STEMI 21.2 % 20.7 % Other 3.7 % 2.8 % p
7 Lesion Characteristics SIROLIMUSELUTING ORSIRO STENT BIOLIMUSELUTING NOBORI STENT No. of lesions 1,590 1,588 No. of lesions per patient Lesion type B2/C Reference vessel size (mm) 3.2 ± ± Left main artery 1.1 % 0.8 % 0.46 Left anterior descending artery 43.1 % 42.3 % Left circumflex artery 21.3 % 22.0 % Right coronary artery 33.1 % 33.7 % Saphenous vein graft 1.4 % 1.2 % No. of stents Per patient 1.5 ± ± Per lesion 1.2 ± ± Total stent length (mm) Per patient 25.2 ± ± Per lesion 20.6 ± ± Direct stenting 14.5 % 13.7% 0.56 Stent delivery failure 1.6 % 2.1 % 0.36 p
8 1º Endpoint: Target Lesion Failure (Cardiac death, myocardial infarction index lesion related, target lesion revascularization) Sirolimuseluting stent 5.2% 4.9% Everolimuseluting stent
9 1º Endpoint: Target Lesion Failure (Cardiac death, myocardial infarction index lesion related, target lesion revascularization) 12 months: ORSIRO 3.8% vs. NOBORI 4.6% P noninferiority < Sirolimuseluting stent NOBORI Everolimuseluting stent ORSIRO 5.2% 4.9% 4.6% 3.8%
10 Secondary Endpoints Rate Ratio % CI ; p=ns Rate Ratio % CI ; p=ns 1.4% 1.3% Sirolimuseluting stent 5.2% 4.9% 2.9% 2.0% Everolimuseluting stent Rate Ratio % CI ; p=ns Rate Ratio % CI ; p=ns 5.2% 4.1% 2.4% 1.6%
11 Stent Thrombosis Rate Ratio % CI ; p=0.03 Rate Ratio % CI ; p=0.11 NOBORI 1.2% Sirolimuseluting stent 5.2% NOBORI 1.6% 4.9% ORSIRO 0.4% Everolimuseluting stent 0.9% ORSIRO
12 Target Lesion Failure In subgroups Acute coronary syndrom NO Acute coronary syndrom YES Age 65 years Age > 65 years Diabetes mellitus NO Diabetes mellitus YES LAD NO LAD YES Lesion type C NO Lesion type C YES Male NO Male YES Multivessel disease NO Multivessel disease YES One stent per patient NO One stent per patient YES Previous MI NO Previous MI YES Previous PCI NO Previous PCI YES STEMI NO STEMI YES All Events (%) Hazard Ratio SES BES 95% CI P 21 (3.5) 27 (4.1) 15 (2.7) 33 (4.7) 37 (3.6) 11 (4.7) 22 (3.5) 26 (4.2) 26 (5.2) 22 (2.9) 13 (4.1) 35 (3.7) 39 (3.6) 9 (5.1) 25 (3.0) 23 (5.5) 36 (3.5) 12 (5.6) 38 (3.8) 10 (4.2) 31 (3.1) 17 (6.4) 48 (3.8) 29 (4.9) 29 (4.3) 28 (4.3) 30 (4.8) 42 (4.1) 16 (6.8) 32 (4.8) 26 (4.3) 33 (6.7) 25 (3.2) 15 (4.8) 43 (4.5) 52 (4.7) 6 (3.9) 39 (4.6) 19 (4.6) 43 (4.2) 13 (5.9) 42 (4.2) 15 (5.9) 46 (4.6) 12 (4.6) 58 (4.6) 0.70 ( ) 0.96 ( ) 0.60 ( ) 0.99 ( ) 0.88 ( ) 0.68 ( ) 0.71 ( ) 0.97 ( ) 0.77 ( ) 0.89 ( ) 0.86 ( ) 0.82 ( ) 0.77 ( ) 1.32 ( ) 0.65 ( ) 1.19 ( ) 0.84 ( ) 0.97 ( ) 0.90 ( ) 0.71 ( ) 0.68 ( ) 1.38 ( ) 0.83 ( ) Favours SES Favours BES
13 Conclusion The thin strut biodegradable polymer sirolimuseluting Orsiro stent was noninferior to the biodegradable polymer biolimuseluting Nobori stent in unselected patients for the combined safety and efficacy endpoint target lesion failure at 1 year The sirolimuseluting Orsiro stent was associated with a reduced risk of definite stent thrombosis SORT OUT VII 1Y
14 SORT OUT VII 1Y
The SORT OUT VI Trial
A Prospective, Randomized, "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Stents The SORT OUT VI Trial Bent Raungaard, Lisette
More informationLisette Okkels Jensen
A Randomized Trial Comparing a Polymer- Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer- Based Drug-Eluting Stent in an All-Comers Patient Population Lisette Okkels Jensen
More informationINTERVENTIONAL CARDIOLOGY nd Annual International Symposium
From the SORT-OUTOUT Trials Lisette Okkels Jensen Professor DMSci PhD FESC Department of Cardiology Odense University Hospital Odense, Denmark INTERVENTIONAL CARDIOLOGY 2017 32nd Annual International Symposium
More information2-Year Patient-Related Versus Stent-Related Outcomes
Journal of the American College of Cardiology Vol. 60, No. 13, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.004
More information3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 8, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.04.008
More informationAalborg Universitet. DOI (link to publication from Publisher): /S (12)61962-X. Publication date: 2013
Aalborg Universitet Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT
More informationBIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions
BIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions Johannes Waltenberger, MD, F.E.S.C. Uniklinik Münster Münster, Germany
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationMid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
More informationSCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationeucalimus - First Experience
A New Sirolimus Eluting Stent with a Biodegradable Polymer Early and Mid Term Experience with the eucalimus Stent in Egypt Dr. Hossam El Din Mohamed Mansour on behalf of the investigators Ahmed Emara,
More informationComparison of zotarolimus-eluting and sirolimuseluting coronary stents: a study from the Western Denmark Heart Registry
Maeng et al. BMC Cardiovascular Disorders 2012, 12:84 RESEARCH ARTICLE Open Access Comparison of zotarolimus-eluting and sirolimuseluting coronary stents: a study from the Western Denmark Heart Registry
More informationInterventional Cardiology
Interventional Cardiology Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention The Scandinavian Organization for Randomized
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationClinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation Lesions
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 11, 2013 ª 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.06.009
More informationThe Nordic Bifurcation Stent Technique Study. A Randomized trial of CRUSH vs CULOTTE Stenting
The Nordic Bifurcation Stent Technique Study A Randomized trial of CRUSH vs CULOTTE Stenting Pål Gunnes, Matti Niemela, Kari Kervinen, Andrejs Erglis, Indulis Kumsars, Jens F Lassen, Michael Mæng, Jan
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationNOBORI 2 Trials One Year Clinical Outcomes
NBRI 2 Trials ne Year Clinical utcomes Dr G.B. Danzi spedale Maggiore Policlinico Milano, Italy INTRDUCTIN Pivotal DES trials enrolled restricted patient population, not truly representative of every day
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationFreedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK
Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,
More informationDrug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2
Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Raban V. Jeger,Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, GregorLeibundgut, Daniel Weilenmann, JochenWöhrle,
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationAppendix: Supplementary material [posted as supplied by author]
Appendix: Supplementary material [posted as supplied by author] Table S1. Full Electronic Search in MEDLINE Database. Search Query Items found 1 Search drug eluting stent 8351 2 Search drug eluting stent
More informationHyeon-Cheol Gwon, On the behalf of SMART-DATE trial investigators ACC LBCT 2018
Six-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE): a randomized, openlabel, multicenter trial
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationAbstract Aims: The aim of the study was to evaluate the two-year clinical outcome of all-comer trial participants
CLINICAL RESEARCH CORONARY INTERVENTIONS Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial Marlies
More informationRemote Ischemic Preconditioning: Current aspects of mechanisms. Hans Erik Bøtker, Aarhus University Hospital, Skejby, Denmark,
Remote Ischemic Preconditioning: Current aspects of mechanisms Hans Erik Bøtker, Aarhus University Hospital, Skejby, Denmark, Mechanisms Dialysate as a bioassay for riperc Shimizu et al. Clin Sci 2009;117:191-200
More informationDauer der doppelten Plättchenhemmung nach AMI / Stent
Dauer der doppelten Plättchenhemmung nach AMI / Stent Kardio-Lunch 04.06.2014 Christoph Kaiser Universitätsspital Basel Christoph.kaiser@usb.ch DAPT after Stenting 257 patients with PCI & stent: ASS &
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationBIOFLOW V Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents
Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents David E Kandzari, MD; Laura Mauri, MD, MSc; Jacques Koolen, MD, PhD; Joseph M Massaro,
More informatione-biomatrix PMS Registry A post market surveillance registry for the BioMatrix TM DES
e-biomatrix PMS Registry A post market surveillance registry for the BioMatrix TM DES Philip Urban La Tour Hospital, Geneva, Switzerland On behalf of the e-biomatrix PMS Registry Investigators: F. Eberli,
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationUltimaster clinical results in left main and bifurcations
Left main and complex bifurcation stenting clinical results in left main and bifurcations GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of Cardiovascular and Pulmonary Sciences
More informationTrial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Seung-Jung Park, MD, PhD On behalf of the BEST investigators Professor of Medicine, University of Ulsan College of
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationOptimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event The DES LATE Trial Cheol Whan Lee, MD, Seung-Jung Park, MD, PhD, On Behalf of the DES LATE Investigators
More informationInspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil
Stent Clinical Research Program Pedro A. Lemos MD PhD Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil All faculty disclosures are available on the CRF Events App and online
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationCPORT E Trial. Atlantic C PORT
CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationIn patients with ST-segment elevation myocardial infarction. Original Research
IMPROVING PATIENT CARE Original Research Health Care System Delay and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention:
More informationImpact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
More informationLong-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023
More informationSTATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION
STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION Otávio Berwanger, MD, FACS - On behalf of the SECURE Steering Committee and Investigators Trial Organization Trial Steering Committee Dr.
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More information7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET)
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET) Hiroki Shiomi, MD Kyoto University Graduate School of Medicine
More informationFor Personal Use. Copyright HMP 2014
Original Contribution Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice Israel M. Barbash, MD, Sa ar Minha,
More informationThe titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath
The titanium nitride oxide stent an alternative to DES Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath Advanced Angioplasty 2008 Declaration of interest I have received an honorarium
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationInsight from Nordic III
Insight from Nordic III Fifth European Bifurcation Club Meeting Berlin 16-17 October 2009 Jens Flensted Lassen, MD, PH.D., FESC. Department of Cardiology Skejby Hospital, University of Aarhus Denmark Nordic-Baltic
More informationSummary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A
Summary HTA HTA-Report Summary Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Scientific background The coronary heart
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationJournal of the American College of Cardiology Vol. 55, No. 9, by the American College of Cardiology Foundation ISSN /10/$36.
Journal of the American College of Cardiology Vol. 55, No. 9, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.052
More informationAlex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
More informationΔημήτριος Αγγοσράς, FETCS
ΣΕΜΙΝΑΡΙΟ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Δημήτριος Αγγοσράς, FETCS Επίκοσρος Καθηγηηής Καρδιοτειροσργικής Ιαηρική Πανεπιζηημίοσ Αθηνών Πανεπιζηημιακό Γενικό Νοζοκομείο Αηηικόν Randomized Controlled Trials (RCTs) Why
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationTIDES-ACS trial. Comparison of TItanium-nitride-oxide coated bioactive stent to the Drug (everolimus)-eluting Stent in Acute Coronary Syndrome
TIDES-ACS trial Comparison of TItanium-nitride-oxide coated bioactive stent to the Drug (everolimus)-eluting Stent in Acute Coronary Syndrome Pasi P Karjalainen Potential conflicts of interest Speaker's
More informationPCI or CABG for severe unprotected left main coronary artery disease: making sense of the NOBLE and EXCEL trials
Editorial PCI or CABG for severe unprotected left main coronary artery disease: making sense of the NOBLE and EXCEL trials Anthony A. Holmes, Sripal Bangalore Leon H. Charney Division of Cardiology, New
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationRemote ischemic conditioning in the STEMI and stroke: are we ready for clinical implementation?
Remote ischemic conditioning in the STEMI and stroke: are we ready for clinical implementation? Hans Erik Bøtker, MD, Ph.D. Aarhus University Hospital Skejby Denmark ACC Rockies 2013 17. March 2013 Presenter
More informationBackground. Drug-eluting stents (DES) are increasingly used in complex patients with a high clinical or lesion-related risk of adverse events.
Complex Patients Treated with Second- Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents in the Randomized TWENTE Trial: Comparison of 2- Year Clinical Outcome Hanim Sen, MD
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches
More information